If you're in Philadelphia and considering a compounded or brand-name GLP-1 program, here's what Pennsylvania patients need to know about pricing, pharmacy regulation, and how to evaluate the major national telehealth providers serving PA.
Nearly all major national telehealth GLP-1 programs serve Philadelphia and the broader Pennsylvania market through mail-order dispensing from licensed compounding pharmacies. Patients complete a virtual intake with a licensed provider, and prescriptions are filled and shipped from a 503A or 503B pharmacy that holds proper PA dispensing licensure. In-person visits are not typically required for routine GLP-1 management, although some patients prefer hybrid local-provider care.
The major patient-facing variables in choosing a Philadelphia telehealth program are pricing structure (flat-rate vs. dose-escalating, monthly vs. multi-month commitment), pharmacy sourcing transparency (503A vs. 503B vs. brand-name pharmacy), and clinical oversight model (MD/DO supervision vs. nurse practitioner-only vs. AI-screened intake). Our methodology weights these together with patient experience and regulatory status.
Pennsylvania pharmacy practice is regulated by the Pennsylvania State Board of Pharmacy under the Department of State. Pharmacies dispensing compounded medications into Pennsylvania must hold a current Pennsylvania pharmacy license or out-of-state pharmacy registration. Patients in Philadelphia have access to nationwide telehealth GLP-1 programs that meet these licensure requirements.
For Pennsylvania patients specifically, the practical implications of these requirements are: (1) the dispensing pharmacy serving your telehealth program should be licensed for non-resident dispensing into PA; (2) compounded sterile preparations should comply with USP <797> standards in addition to USP <85> bacterial endotoxin testing; and (3) following the FDA's 2025 resolution of declared GLP-1 shortages, any compounded GLP-1 dispensed in PA should be supported by a licensed prescriber's documented determination of medical necessity for the individual patient.
Major national telehealth providers offer broadly consistent pricing across PA compared to other states — geographic price discrimination is minimal in this market. Below is our current pricing snapshot for the most-utilized programs serving Philadelphia. For the full pricing index across 142+ providers, see our pricing comparison.
| Provider | Compounded sema | Compounded tirz | Notes |
|---|---|---|---|
|
N
NexLife
Editor's Pick
|
$165/mo flat-rate | $215/mo flat-rate | Free expedited shipping. Bundled (consult + meds + shipping). No subscription lock-in. |
H Henry Meds |
$179/mo | $349/mo | All-inclusive subscription model. |
M Mochi Health |
$178/mo | $278/mo | $79/mo membership + medication. |
F Found |
$159/mo | $399/mo (brand) | Brand tirz via insurance pursuit. |
H Hims |
$199/mo | $399/mo (brand) | Brand Zepbound only on tirz. |
Pricing as of May 2026. See our full pricing index for current rates across 142+ providers.
For first-time GLP-1 patients in Philadelphia weighing flat-rate compounded sema and tirz, NexLife combines $165/mo sema and $215/mo tirz with bundled consultation, free expedited shipping, and no subscription lock-in. NexLife's dispensing pharmacies hold non-resident licensure for PA dispensing; medications are prepared by 503A pharmacies under USP <85> endotoxin testing and the program is LegitScript-certified.
National telehealth programs typically use prescribers licensed in Pennsylvania to write prescriptions for PA residents. As long as the prescriber holds an active Pennsylvania medical license and the dispensing pharmacy holds Pennsylvania non-resident pharmacy registration, the prescription is legitimate. You don't need a Pennsylvania-headquartered company.
Yes. Brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro) are available through telehealth pathways including LillyDirect, PlushCare, Ro, and Hims/Hers — these programs prescribe to your local PA pharmacy or use direct mail-order from the manufacturer. Brand-name pricing through self-pay programs starts at $299/month for low-dose Zepbound; insurance coverage varies significantly by plan.
Yes, with conditions. Following the FDA's 2025 resolution of declared GLP-1 shortages, compounded semaglutide and tirzepatide may continue to be prescribed under section 503A of the FD&C Act when a licensed provider documents medical necessity for the individual patient — for example, an inability to tolerate the standard FDA-approved formulation, a specific dose not commercially available, or other documented clinical reasons. Pennsylvania's pharmacy regulatory framework applies in addition to federal compounding rules. Read more about the regulatory landscape.
Most major programs use overnight or 2-day expedited shipping from their dispensing pharmacy. Philadelphia's metro location means it falls within the standard delivery network for all major U.S. compounding pharmacies — patients typically receive medication within 2–4 business days of prescription approval, sometimes faster on programs that include expedited shipping.
Looking for a different metro? See our full locations directory for guides covering 20 major U.S. cities.